May 27 2022




Recommendations

Propoxyphene is considered compatible with breastfeeding. However, the most controversial aspect of this drug is its conversion partial in norpropoxyphene, 25% of the administered dose. This substance has a prolonged half-life period, accumulating in the milk first, and after in the infant. The norpropoxyphene has neurotoxic and cardiotoxic properties.

Some studies of small numbers of patients and cases referred individually indicate the appearance of apnea, cyanosis and bradycardia in neonates whose mothers received propoxyphene, being attributed these symptoms to this drug, forcing closer watch on babies whose mothers have been treated with propoxyphene.

It is advisable to supplement maternal treatment with non-narcotic analgesics and minimize the dose of propoxyphene, in anticipation of the onset of neurological or cardiorespiratory depression, especially during the neonatal period.

It is estimated that breast fed infant could receive up to 32 mcg / kg / day of propoxyphene and an amount three times more of norpropoxyphene.

Warning of the manufacturer:

This substance is excreted in breast milk in small amounts. No adverse effects have been reported in infants, so it is considered that the use of propoxyphene is compatible with breastfeeding, however it is recommended not start or resume breastfeeding up to 4-6 h after administration of the drug.

Updated:01.03.08